Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-wide CRISPR/Cas9 screening in human iPS derived cardiomyocytes uncovers novel mediators of doxorubicin cardiotoxicity.

Scientific reports - 6 Jul 2021

Sapp Valerie, Aguirre Aitor, Mainkar Gayatri, Ding Jeffrey, Adler Eric, Liao Ronglih, Sharma Sonia, Jain Mohit

Abstract excerpt

Human induced pluripotent stem (iPS) cell technologies coupled with genetic engineering now facilitate the study of the molecular underpinnings of disease in relevant human cell types. Application of CRISPR/Cas9-based approaches for genome-scale functional screening in iPS-derived cells, however, has been limited by technical constraints, including inefficient transduction in pooled format, loss of library...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiotoxicity
Share to CRISPR-Cas Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Doxorubicin

Share to Genome, Human

Share to Induced Pluripotent Stem Cells

Share to Lentivirus

Share to Myocytes, Cardiac

Share to RNA, Guide, CRISPR-Cas Systems

Source

Open in PubMed Open full text

Identifiers

PMID: 34230586
DOI: 10.1038/s41598-021-92988-1
PMCID: PMC8260754

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide CRISPR/Cas9 screening in human iPS derived cardiomyocytes uncovers novel mediators of doxorubicin cardiotoxicity.PMID 34230586Read ↗

Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity.Semantic proximity Read ↗

Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related GenesSemantic proximity Read ↗

Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-CardiomyocytesSemantic proximity Read ↗

Targeted CRISPR activation and knockout screenings identify novel drug transportersSemantic proximity Read ↗

Thousand and one amino acid protein kinase 1 suppression improves doxorubicin-induced cardiomyopathy by preventing cardiomyocyte death and dysfunctionSemantic proximity Read ↗

Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.Semantic proximity Read ↗

Towards Precision Medicine With Human iPSCs for Cardiac ChannelopathiesSemantic proximity Read ↗

Preconditioning of human iPSCs with doxorubicin causes genome-wide transcriptional reprogramming in iPSC-derived cardiomyocytes linked to mitochondrial dysfunction and impaired cardiac regenerationSemantic proximity Read ↗

Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.Semantic proximity Read ↗

Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessmentSemantic proximity Read ↗

Personalized medicine in cardio-oncology: the role of induced pluripotent stem cellSemantic proximity Read ↗

Transcriptomic profiling reveals p53 as a key regulator of doxorubicin-induced cardiotoxicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.